Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 174

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 174
---
 any matters arising from its review of compensation practices; and

evaluating the function of the Compensation Committee on an annual basis.

Nominating Committee

The primary function of the Nominating Committee, in accordance with its charter, is to assist the Board in fulfilling its responsibility to oversee our nominating procedures.

The Nominating Committee is required to review and assess the adequacy of its charter periodically as conditions dictate, but at least annually, to ensure compliance with any rules or regulations and recommend any modifications to its charter if and when appropriate to the Board for its approval.

Nominating Committee Composition

As of the date of this prospectus, the Nominating Committee is comprised of Dr. Sara R. May, Dr. Larry Kaiser, the Hon. Cathy McMorris Rodgers and Robert J. Ciaruffoli, all of whom are considered independent.

Nominating Committee Charter

The Board has adopted a written charter for the Nominating Committee, which sets out the Compensation Committee's responsibilities, including;

making recommendations to the Board with respect to the size, composition and structure of the Board;

making recommendations to the Board with respect to the reorganization of responsibilities among committees, the creation of additional committees or subcommittees, or the elimination of committees;

making recommendations to the Board with respect to the preferred experience and qualifications of news directors to be elected by shareholders;

making recommendations to the Board with respect to qualified candidates for nomination for election to the Board at each annual general meeting of shareholders;

making recommendations to the Board with respect to the appointment of qualified directors to each committee;

<div align='center'>119

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83</div>

making recommendations to the Board with respect to developing and overseeing an orientation program for new directors and a continuing education program for current directors;

making recommendations to the Board with respect to Board succession; and

conducting annual performance assessments of the Board.

Executive Compensation

Named Executive Officers

Compensation of our named executive officers generally consists of the following elements: base salaries and participation in our equity incentive plan. The following table sets forth all compensation awarded to, or earned by, our named executive officers for the years ended December 31, 2024 and 2023.

| Name and            
 principal position  
 Dr. Raza Bokhari,   
 (1) CEO             |  Fiscal Year 
        Ended 
 December 31, 
         2024